Phase II Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors
The purpose of this phase II trial is to evaluate the safety and efficacy of belzutifan (MK-6482) in patients with advanced pheochromocytoma/ paraganglioma (PPGL) or pancreatic neuroendocrine tumors (pNET).
Study ID: 6482-015
Trial Phase: Phase II
Trial Sponsor: Merck Sharp & Dohme Corp.
Therapies Used in This Trial: Belzutifan